Zobrazeno 81 - 90
of 267
pro vyhledávání: '"Cornelia Liedtke"'
Autor:
Anton Scharl, Elmar Stickeler, Thomas Papathemelis, Annette Salterberg, Michael Untch, Cornelia Liedtke
Publikováno v:
Oncology research and treatment. 39(3)
Patients not older than 40 years are referred to as young patients. These women benefit from chemo-, endocrine and anti-HER2 therapy to a similar degree as older women. Surgery and radiation therapy also follow the same recommendations. This manuscri
Autor:
Rachel Würstlein, V. Heyl, Nadia Harbeck, F Lorenz-Salehi, Clemens, Cornelia Liedtke, Tom Degenhardt, O Gluz, U. Nitz, Matthias Christgen, H.H. Kreipe, Benno Nuding, Christoph Uleer, A. Stefek, Stefan Kraemer, Marianne Just, S. Kuemmel, Toralf Reimer, Bahriye Aktas, Ronald E. Kates
Publikováno v:
Geburtshilfe und Frauenheilkunde. 76
Autor:
Christoph Gerlinger, S Stein, Cornelia Liedtke, Rainer M. Bohle, EF Solomayer, Achim Rody, I Juhasz-Böss, Gilda Schmidt, Pauline Wimberger, Elmar Stickeler, Tanja Fehm, E Müller
Publikováno v:
Geburtshilfe und Frauenheilkunde. 76
Publikováno v:
Lancet (London, England). 389(10087)
Summary Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different subgroups of triple-neg
Autor:
Cornelia Liedtke, Erich-Franz Solomayer, Maria Karsten, Julia Caroline Radosa, Melissa Pilewskie, Michelle Stempel, Tari A. King, Anne Eaton, Monica Morrow, Amrin Khander
Publikováno v:
Annals of surgical oncology. 24(3)
Triple-negative breast cancer (TNBC) subtype and young patient age are both associated with an increased risk of local recurrence (LR) and distant recurrence (DR). In young women with TNBC, it is unclear whether subtype or patient age is driving prog
Autor:
Achim Rody, Cornelia Liedtke
Publikováno v:
Reviews on recent clinical trials. 12(2)
Patients with triple negative breast cancer (TNBC) are characterized by an unfavorable prognosis particularly when not responding well to anthracycline-taxane chemotherapy. This is due to a more aggressive biology in some cases but most importantly t
Publikováno v:
Reviews on recent clinical trials. 12(2)
Primary endocrine therapy is an option in cases of hormone receptor positive and HER2 negative non-metastatic breast cancer. Aromatase inhibitors are considered the therapy of choice in postmenopausal patients. In premenopausal patients aromatase inh
Autor:
Cornelia Liedtke, Friederike Klein
Publikováno v:
Im Focus Onkologie. 21:11-12
Patientinnen mit HER2-negativem Mammakarzinom und residualem Tumor nach einer neoadjuvanten Chemotherapie haben eine ungunstige Prognose. Ob eine adjuvante Chemotherapie ihr Behandlungsergebnis verbessert, wurde in der Studie CREATE-X untersucht.
Autor:
Tanja Fehm, H-C Kolberg, Maik Hauschild, Lukas Schwentner, Barbara Fleige, Cornelia Liedtke, A Stäbler, P Schrenk, Sabine Schmatloch, Thorsten Kühn, Gisela Helms, Annette Lebeau, Ingo Bauerfeind, Michael Untch, S. Loibl
Publikováno v:
Cancer Research. 79:PD8-02
Background:The association between pathological complete remission (pCR) in the breast and clinical/pathological parameters is well established, whereas the role of these parameters in the prediction of residual axillary involvement after NACT is unc
Autor:
Annette Staebler, Ingo Bauerfeind, Maja Krajewska, Barbara Fleige, H-C Kolberg, Annette Lebeau, Gisela Helms, S. Loibl, Cornelia Liedtke, Thorsten Kühn, Tanja Fehm, Michael Untch
Publikováno v:
Cancer Research. 79:PD8-03
Background: Modern chemotherapy carries a high potential of converting patients with clinically suspicious axillary nodes (cN+) prior to PST to clinically (ycN0) or pathologically (ypN0) negative nodes after PST. Clinical and sonographical axillary a